News | August 08, 2007

CAD Marks 96 Percent of Cancers Detected with FFDM

August 9, 2007 - Hologic Inc. announced that, according to a recent independent peer-reviewed study published in the July issue of Radiology, computer aided detection correctly marked 99 (96.1 percent) of 103 consecutive asymptomatic breast cancers detected with digital mammographic screening, with an acceptable false marker rate (1.80 false CAD marks per patient). The CAD system (ImageChecker M1000 version 3.1) used in this study was from Hologic’s R2 Technology subsidiary.

Yang and co workers, from the Seoul National University Medical Research Center, reported that the R2 CAD system “marked all 44 breast cancers that manifested as microcalcifications only, all 23 breast cancers that manifested as a mass with microcalcifications and 32 (89 percent) of 36 lesions that appeared as a mass only.” “We are pleased that this study (the first to be published on R2 digital CAD by an independent medical facility) showed such strong results. Of particular note, CAD correctly marked the single invasive lobular carcinoma lesion and 67 of 71 (94.4 percent) of invasive ductal carcinomas, of which 22 had a component of DCIS. As digital mammography gains wider acceptance, R2’s CAD will continue to be a valuable tool to assist radiologists in the earlier detection of breast cancer”, said Dr. Ronald A. Castellino, R2 Technology’s chief medical officer.

Hologic|R2 continues to develop and refine it’s CAD solutions and is currently marketing ImageChecker V8.3 for digital mammography.

For more information: www.r2tech.com and www.hologic.com

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad Companion Chest CT,...
Telerad Tech Launches MammoAssist AI Software
Technology | Computer-Aided Detection Software | January 25, 2019
Telerad Tech recently announced the launch of MammoAssist, a new artificial intelligence (AI) product to analyze and...
Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...